Nearly 85% of proteins are considered ‘undruggable’, meaning they cannot be inhibited using traditional small molecule drugs, and therapeutic targeting of these ‘undruggable’ proteins remains a major challenge in drug development. Therapeutic inhibition of protein-protein interactions (PPIs) is an attractive approach for drugging the undruggable since most proteins require specific interactions to function, however, targeting PPIs remains challenging. This technology is a novel drug discovery platform for identifying PPI inhibitors.